89 related articles for article (PubMed ID: 20821805)
21. [Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer].
Meguro N; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
Hinyokika Kiyo; 1998 Sep; 44(9):639-43. PubMed ID: 9805668
[TBL] [Abstract][Full Text] [Related]
22. Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer.
Ricciardelli C; Mayne K; Sykes PJ; Raymond WA; McCaul K; Marshall VR; Tilley WD; Skinner JM; Horsfall DJ
Clin Cancer Res; 1997 Jun; 3(6):983-92. PubMed ID: 9815775
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker.
Hernández J; Thompson IM
Cancer; 2004 Sep; 101(5):894-904. PubMed ID: 15329895
[TBL] [Abstract][Full Text] [Related]
24. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
[TBL] [Abstract][Full Text] [Related]
25. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer.
Gross M; Top I; Laux I; Katz J; Curran J; Tindell C; Agus D
Clin Cancer Res; 2007 Apr; 13(7):1979-86. PubMed ID: 17404077
[TBL] [Abstract][Full Text] [Related]
26. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase.
Wang J; Weng J; Cai Y; Penland R; Liu M; Ittmann M
Prostate; 2006 Jun; 66(8):847-57. PubMed ID: 16491480
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker.
Mulders TM; Bruning PF; Bonfrer JM
Eur J Surg Oncol; 1990 Feb; 16(1):37-41. PubMed ID: 1689677
[TBL] [Abstract][Full Text] [Related]
28. "Product ion monitoring" assay for prostate-specific antigen in serum using a linear ion-trap.
Kulasingam V; Smith CR; Batruch I; Buckler A; Jeffery DA; Diamandis EP
J Proteome Res; 2008 Feb; 7(2):640-7. PubMed ID: 18186600
[TBL] [Abstract][Full Text] [Related]
29. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
Tarle M; Kraljić I
Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
[TBL] [Abstract][Full Text] [Related]
30. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
Gomella LG; Raj GV; Moreno JG
J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297
[TBL] [Abstract][Full Text] [Related]
31. New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era.
Bickers B; Aukim-Hastie C
Anticancer Res; 2009 Aug; 29(8):3289-98. PubMed ID: 19661347
[TBL] [Abstract][Full Text] [Related]
32. Development of novel peptide ligands modulating the enzyme activity of prostate-specific antigen.
Leinonen J; Wu P; Koivunen E; Närvänen A; Stenman UH
Scand J Clin Lab Invest Suppl; 2000; 233():59-64. PubMed ID: 11317943
[TBL] [Abstract][Full Text] [Related]
33. Detecting prostate cancer by intracellular macrophage prostate-specific antigen (PSA): a more specific and sensitive marker than conventional serum total PSA.
Herwig R; Mitteregger D; Djavan B; Kramer G; Margreiter M; Leers MP; Glodny B; Haider DG; Hörl WH; Marberger M
Eur J Clin Invest; 2008 Jun; 38(6):430-7. PubMed ID: 18489403
[TBL] [Abstract][Full Text] [Related]
34. Combination of improved (18)O incorporation and multiple reaction monitoring: a universal strategy for absolute quantitative verification of serum candidate biomarkers of liver cancer.
Zhao Y; Jia W; Sun W; Jin W; Guo L; Wei J; Ying W; Zhang Y; Xie Y; Jiang Y; He F; Qian X
J Proteome Res; 2010 Jun; 9(6):3319-27. PubMed ID: 20420461
[TBL] [Abstract][Full Text] [Related]
35. Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples.
Egawa S; Suyama K; Matsumoto K; Kuwao S; Baba S
J Urol; 2002 Jan; 167(1):97-102. PubMed ID: 11743284
[TBL] [Abstract][Full Text] [Related]
36. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry.
Garbis SD; Tyritzis SI; Roumeliotis T; Zerefos P; Giannopoulou EG; Vlahou A; Kossida S; Diaz J; Vourekas S; Tamvakopoulos C; Pavlakis K; Sanoudou D; Constantinides CA
J Proteome Res; 2008 Aug; 7(8):3146-58. PubMed ID: 18553995
[TBL] [Abstract][Full Text] [Related]
37. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
Tsuchiya N; Ohyama C; Habuchi T
Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
[TBL] [Abstract][Full Text] [Related]
38. PSA and PAP as immunohistochemical markers in prostate cancer.
Epstein JI
Urol Clin North Am; 1993 Nov; 20(4):757-70. PubMed ID: 7505984
[TBL] [Abstract][Full Text] [Related]
39. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
[TBL] [Abstract][Full Text] [Related]
40. Plasma low-molecular-weight proteome profiling identified neuropeptide-Y as a prostate cancer biomarker polypeptide.
Ueda K; Tatsuguchi A; Saichi N; Toyama A; Tamura K; Furihata M; Takata R; Akamatsu S; Igarashi M; Nakayama M; Sato TA; Ogawa O; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
J Proteome Res; 2013 Oct; 12(10):4497-506. PubMed ID: 23991666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]